WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles:
Related suggestion:
Saweetie and YG Marley look cozy as they put on a lovedWorld Internet SciNew study interlinks super dust storm, aerosol radiative feedbackJiangsu continues supporting technological innovation of industriesInside Lily James' idyllic childhood as the daughter of a musician and actressWorld Internet SciFeature: ChineseChinese Embassy lashes out at U.S. over harassing Chinese citizens at borderWhat key recent events led to Iran's assault on Israel?SE China's Quanzhou drives high
3.0869s , 4667.1328125 kb
Copyright © 2024 Powered by US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition ,Global Grid news portal